Navigation Links
Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
Date:11/2/2010

cluding, without limitation: our dependence on the successful commercialization of OFIRMEV; the potential that we will require substantial additional funding in order to effectively commercialize OFIRMEV, and the risk that we may not be able to raise sufficient capital when needed, or at all; the risk that delays in commercially launching OFIRMEV would enable competitors to further entrench their existing products or develop and bring new products to market before OFIRMEV; our ability to ensure an adequate and continued supply of OFIRMEV to successfully launch commercial sales or meet anticipated market demand; our ability to comply with the terms of our loan agreement, and draw down additional amounts under our loan agreement; the potential for an event of default under our loan agreement, and the corresponding risk of acceleration of repayment and potential foreclosure on the assets pledged to secure the line of credit; the impact of healthcare reform legislation; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence™ and OFIRMEV™ are trademarks of Cadence Pharmaceuticals, Inc.  Contacts:INVESTORS

MEDIACadence Pharmaceuticals, Inc.

WCGWilliam R. LaRue, SVP and Chief Financial Officer

Hayley Soffer858-436-1400

212-301-7176blarue@cadencepharm.com

hsoffer@w
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
10. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 LabStyle ... Diabetes Management Solution, today announced it recently closed ... Funds will be used to support the global ... Dario, a mobile, cloud-based, diabetes management solution that ... ,all-in-one, pocket-sized, blood glucose monitoring device, and for ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... priority in the drug development approval process. Thus, innovator companies must understand what ... Technologies, Inc., a Chicago-based CMO, has been hosting multiple educational panels and seminars ...
(Date:8/31/2015)... ... 31, 2015 , ... There’s a new treatment option for excessive menstrual bleeding ... new FDA approved system in the last 14 years, and the only endometrial ablation ... bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and the fastest ...
(Date:8/30/2015)... England , August 31, 2015 /PRNewswire/ ... 51-jährige Wartezeit   einer Frau   für chirurgische   ... Alter von 7-90   werden für eine ... Programm soll 1200 Frauen behandeln und die Anzahl ausgebildeter ... Astellas gab heute bekannt, dass  Action ...
Breaking Biology Technology:LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... researchers have made a breakthrough in understanding the effect ... pollution. The discovery could lead to more accurate forecasting ... Anderson. , Crozier is an associate professor in ASU,s ... College of Liberal Arts and Sciences and the Ira ...
... Verenium Corporation,(Nasdaq: VRNM ), a leading developer ... development of high-performance specialty enzymes, announced,today that Gerald ... at,the upcoming Canaccord Adams 28th Annual Global Growth ... a.m. ET on Thursday, August 14,and will take ...
... Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced today that ... an update on the company,s business,at the Thomas Weisel ... a.m. (Eastern Time) at the Four Seasons Hotel in ... the subsequent archived,recording, log on to http://www.monogrambio.com ...
Cached Biology Technology:Forward step in forecasting global warming 2Forward step in forecasting global warming 3Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference 2Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference 3Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008 2
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... Tampa, Fla. (Dec, 19 2011) A ... into rats modeled with amyotrophic lateral sclerosis (ALS), ... lethal, neuromuscular disease, have tested four different immunosuppressive ... therapeutic effects. Their study demonstrated that a combined, ...
... Tampa, Fla. (Dec, 19 2011) Bone marrow-derived stem ... because they can contribute to different cell populations in a ... BMDC studies have been aimed at repairing damaged brain tissue ... focused on BMDC transplants to the cerebellum at the back ...
... disease drug discovery, MMV and SCYNEXIS, Inc. have assembled a ... antimalarial activity and will provide it to researchers at no ... confirmed activity against the blood-stage of P. falciparum ... were selected by experienced medicinal chemists from an extensive screening ...
Cached Biology News:Grafting of human spinal stem cells into ALS rats best with immunosuppressant combination 2Bone marrow-derived cells differentiate in the brain through mechanisms of plasticity 2MMV and SCYNEXIS offer 400 active compounds for neglected disease drug research at no cost 2
Mouse Activin RIB/ALK-4 MAb (Clone 207304)...
... 19 x 29 cm, 1. One ... staining of Coomassie Blue or silver-stain gels ... blots for high sensitivity ECL detection and ... volume, and processing time.Proven design for consistent, ...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
... Reagent Pack, 1. Contains reagents for ... mouse and rabbit primary antibodies. Designed for ... reagents are not included, but the system ... Category: Blotting & Labeling & Detection, ...
Biology Products: